Gambardella Alessio, Licata Gaetano, De Rosa Alina, Calabrese Giulia, Alfano Roberto, Argenziano Giuseppe
Drs. Gambardella, Licata, De Rosa, Calabrese, Argenziano are with the Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine at the University of Campania Luigi Vanvitelli in Naples, Italy.
Dr. Alfano is with the Department of Anesthesiology, Surgery and Emergency at the University of Campania Luigi Vanvitelli in Naples, Italy.
J Clin Aesthet Dermatol. 2022 Feb;15(2):23-25.
Recently it has been reported that apremilast might promote melanogenesis and it would therefore not be safe to use this drug in patients with psoriasis who have a history of melanoma.
From January 2017 to December 2020, we retrospectively identified, within a cohort of 635 patients in follow-up care for melanoma, 16 cases of patients with psoriasis treated with apremilast and history of melanoma. Patients were monitored at our unit for a mean duration of 36 months of follow up.
The use of apremilast, in our case series was, thus, effective in managing psoriasis without causing recurrence of previous melanoma or any new suspicious lesions which would need removal.
It has been speculated that apremilast might not be safe in patients who have a history of melanoma as it would be involved in the stimulation of melanogenesis and consequent possibility of recurrence of previous melanoma.
Our data show that none of the patients treated with apremilast developed recurrence of melanoma at 36 months of follow-up. Further studies are necessary to confirm the safety of apremilast in a larger number of patients with concurrent malignancies, specifically melanoma, and for a longer follow-up period.
最近有报道称阿普司特可能会促进黑色素生成，因此对于有黑色素瘤病史的银屑病患者使用该药可能不安全。
2017年1月至2020年12月，我们在一组635例接受黑色素瘤随访的患者中，回顾性地确定了16例有黑色素瘤病史且接受阿普司特治疗的银屑病患者。这些患者在我们科室接受了平均36个月的随访监测。
在我们的病例系列中，使用阿普司特有效地控制了银屑病，未导致既往黑色素瘤复发或出现任何需要切除的新的可疑病变。
据推测，阿普司特对于有黑色素瘤病史的患者可能不安全，因为它可能会刺激黑色素生成，进而导致既往黑色素瘤复发。
我们的数据显示，接受阿普司特治疗的患者在36个月的随访中均未出现黑色素瘤复发。需要进一步研究以证实阿普司特在更多合并恶性肿瘤（特别是黑色素瘤）患者中的安全性，并进行更长时间的随访。
